WE WILL BE STELLAR THIS YEAR 2024.

WE ARE PREPARING INTERESTING PAPERS NOW!

WE NEED A TALENTED FUTURE RESEARCHER WORKING TOGETHER!

​

Dr. Kim Kyung A's work on Fusobacterium in colon cancer was submitted to Cancer Discovery!

Yura is preparing her first manuscript on exosomal protein as a diagnostic biomarker.
We finalized the Exosome-DNA paper in Nature Cancer
KRAS screening paper is now online in Cancer Letters (Apr 2024)!

​​

<2024>

[68] Site-Specific Mutagenesis Screening in KRASG12D Mutant Library to Uncover Resistance Mechanisms to KRASG12D Inhibitors

Choi J*, Shin JY*, Kim TK*, Kim K, Kim J, Jeon E, Park J, Han YD, Kim KA, Sim T, Kim HK#, Kim HS#. Cancer Letters. 2024:216904 (#correspondence)

*Tae Yul Kim did a really great experiment to wrap up the study.

[67] Synthetic Data Improve Survival Status Prediction Models in Early-Onset Colorectal Cancer

Kim H, Jang WS, Sim WS, Kim HS, Choi JE, Baek ES, Park YR, Shin SJ. JCO Clin Cancer Inform. 2024;8:e2300201

​

<2023>

[66] Hepatic arterial infusion in combination with systemic chemotherapy in patients with hepatic metastasis from colorectal cancer: a randomized phase II study - (NCT05103020) - study protocol. Kim JS, Kim H, Lee SY, Han YD, Han K, Min BS, Kim MD, Won JY, Beom SH, Shin SJ, Kim HS#, Han DH#, Ahn JB#. BMC cancer. 2023;23(1):691 (#co-correspondence)

[65] Antioxidant Iron Oxide Nanoparticles: Their Biocompatibility and Bioactive Properties KLee J, Lee JH, Lee SY, Park SA, Kim JH, Hwang D, Kim KA, Kim HS. Int J Mol Sci. 2023;24(21):15901

[64] Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP Kim M, Shim HS, Kim S, Lee IH, Kim J, Yoon S, Kim HD, Park I, Jeong JH, Yoo C, Cheon J, Kim IH, Lee J, Hong SH, Park S, Jung HA, Kim JW, Kim HJ, Cha Y, Lim SM, Kim HS, Lee CK, Kim JH, Chun SH, Yun J, Park SY, Lee HS, Cho YM, Nam SJ, Na K, Yoon SO, Lee A, Jang KT, Yun H, Lee S, Kim JH, Kim WS. Cancer Res Treat. 2023;DOI: 10.4143/crt.2023.1043

[63] Active involvement of patients, radiation oncologists, and surgeons in a multidisciplinary team approach: Guiding local therapy in recurrent, metastatic rectal cancer 
Choi SH, Yang G, Koom WS, Yang SY, Kim SS, Lim JS, Kim HS, Shin SJ, Chang JS. Cancer Med. 2023;12(22):21057-21067
[62] Spatial and clonality-resolved 3D cancer genome alterations reveal enhancer-hijacking as a potential prognostic marker for colorectal cancer

Kim K, Kim M, Lee AJ, Song SH, Kang JK, Eom J, Kang GH, Bae JM, Min S, Kim Y, Lim Y, Kim HS, Kim YJ, Kim TY, Jung I. Cell Rep. 2023;42(7):112778

[61] Identification of novel pathogenic roles of BLZF1/ATF6 in tumorigenesis of gastrointestinal stromal tumor showing Golgi-localized mutant KIT.

Kwon Y, Kim J, Cho SY, Kang YJ, Lee J, Kwon J, Rhee H, Bauer S, Kim HS, Lee E, Kim HS, Jung JH, Kim H, Kim WK.
Cell Death Differ. 2023;30(10):2309-2321

[60] Development of a deep learning based image processing tool for enhanced organoid analysis

Park T, Kim TK*, Han YD, Kim KA, Kim H, Kim HS#. Sci Rep. 2023;13(1):19841 (#correspondence)

[59] Effect of High-Versus Low-Frequency of Abdominopelvic Computed Tomography Follow-Up Testing on Overall Survival in Patients With Stage II Or III Colon Cancer

Jeon J, Lee DB, Shin SJ, Han DH, Chang JS, Han YD, Kim H, Lim JS, Kim HS#, Ahn JB#. Clinical Colorectal Cancer. 2023 (#correspondence)

[58] Tumour extracellular vesicles and particles induce liver metabolic dysfunction

Wang G, Li J, Bojmar L, Chen H, Li Z, Tobias GC, Hu M, Homan EA, Lucotti S, Zhao F, Posada V, Oxley PR, Cioffi M, Kim HS, Wang H, Lauritzen P, Boudreau N, Shi Z, Burd CE, Zippin JH, Lo JC, Pitt GS, Hernandez J, Zambirinis CP, Hollingsworth MA, Grandgenett PM, Jain M, Batra SK, DiMaio DJ, Grem JL, Klute KA, Trippett TM, Egeblad M, Paul D, Bromberg J, Kelsen D, Rajasekhar VK, Healey JH, Matei IR, Jarnagin WR, Schwartz RE, Zhang H, Lyden D. Nature. 2023.May 24. doi: 10.1038/s41586-023-06114-4

[57] Bleeding risk and mortality according to antithrombotic agents' exposure in cancer-related stroke patients: nationwide population-based cohort study in South Korea

Choi BK, Lee JS, Kim HR, Kim HS Jung YH, Park YR. BMC Neurol. 2023;23(1):187. doi: 10.1186/s12883-023-03208-4

[56] Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination

Huh HD, Sub Y, Oh J, Kim YE, Lee JY, Kim HR, Lee S, Lee H, Pak S, Amos SE, Vahala D, Park JH, Shin JE, Park SY, Kim HS, Roh YH, Lee HW, Guan KL, Choi YS, Jeong J, Choi J, Roe JS, Gee HY, Park HW. Mol Cancer. 2023;22(1):63. doi: 10.1186/s12943-023-01753-7

[55] Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma

Cheon J, Kim H, Kim HS, Kim CG, Kim I, Kang B, Kim C, Jung S, Ha Y, Chon HJ. Ther Adv Med Oncol. 2023. doi: 10.1177/17588359221148541

[54] Investigation of the trajectory of muscle and body mass as a prognostic factor in colorectal cancer patients: A longitudinal cohort study

Seo D*, Kim HS*, Ahn JB, Park YR. JMIR Public Health Surveill. 2023;0:e0 doi: 10.2196/43409 (*co-first)

[53] Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers

Kim HS*, Kim CG*, Kim W*, Kim K*, Yoo J, Min BS, Paik S, Shin SJ, Lee H, Lee K, Kim H, Shin E#, Kim T#, Ahn JB#. Front. Cell. Infect. Microbiol. 2023;13 doi: 10.3389/fcimb.2023.1101291 (*co-first)

[52] Machine learning-based mortality prediction model for critically ill cancer patients admitted to the intensive care unit (CanICU)

Ko R*, Cho J*, Shin M, Oh SW, Seong Y, Jeon J, Jeon K, Paik S, Lim JS, Shin SJ, Ahn JB, Park JH, You SC#, Kim HS#. cancers. 2023;15(3):569. doi: 10.3390/cancers15030569. (#correspondence)

[51] Increasing disparities in the proportions of active treatment and 5-year overall survival over time by age groups among older patients with gastric cancer in Korea

Zhang HS, Choi DW, Kim HS, Kang HJ, Jhang H, Jeong W, Nam CM, Park S. Front Public Health. 2023;10:1030565. doi: 10.3389/fpubh.2022.1030565.

​

<2022>

[50] Detection of circulating KRAS mutant DNA in extracellular vesicles using droplet digital PCR in patients with colon cancer

Choi J*, Cho HY*, Jeon J, Kim K, Han YD, Ahn JB, Wortzel I, Lyden D, Kim HS#. Front Oncol. 2022;12:1067210. doi:10.3389/fonc.2022.106721 0 (#correspondence)

[49] BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling

Shaashua L, Ben-Shmuel A, Pevsner-Fischer M, Friedman G, Levi-Galibov O, Nandakumar S, Barki D, Nevo R, Brown LE, Zhang W, Stein Y, Lior C,
Kim HS, Bojmar L, Jarnagin WR, Lecomte N, Mayer S, Stok R, Bishara H, Hamodi R, Levy-Lahad E, Golan T, Porco JA Jr, Iacobuzio-Donahue CA,
Schultz N, Tuveson DA, Lyden D, Kelsen D, Scherz-Shouval R. Nat Commun. 2022;13(1):6513. doi: 10.1038/s41467-022-34081-3.

[48] Periodontal disease and cancer risk: A nationwide population-based cohort study

Kim CM, Lee JB, Shin SJ, Ahn JB, Lee M#, Kim HS#. ESMO Open. 2022;7(5):100577. doi:10.1016/j.esmoop.2022.100577 (#co-correspondence)

[47] Magnetofluoro-Immunosensing Platform Based on Binary Nanoparticle-Decorated Graphene for Detection of Cancer Cell-Derived Exosomes

Lee J, Lee JH, Mondal J, Hwang J, Kim HS, Kumar V, Raj A, Hwang SR, Lee YK. Int J Mol Sci. 2022;23(17):9619. doi: 10.3390/ijms23179619.

[46] Periodontal disease and cancer risk: A nationwide population-based cohort study

Kim EH*, Nam S, Park CH, Kim Y, Lee M, Ahn JB, Shin SJ, Park YR, Jung HI, Kim BI, Jung I#, Kim HS*,#. Front Oncol. 2022;12:901098. doi: 10.3389/fonc.2022.901098 (*co-first, #co-correspondence) - The epidemiologic data implying putative role of F. nucleatum in colon cancer

[45] The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma

Kim HS, Kim CG, Hong JY, Kim IH, Kang B, Jung S, Kim C, Shin SJ, Choi HJ, Cheon J, Chon HJ, Lim HY. Ther Adv Med Oncol.  2022 Jul 16; 14:17588359221113266. doi: 10.1177/17588359221113266

[44] Importance of Local Ablative Therapies for Lung Metastases in Patients With Colorectal Cancer

Lee BM, Chang JS, Koom WS, Byun HK, Kim HS, Beom SH, Oh C, Suh YJ, Ahn JB, Shin SJ, Park BJ, Park SY. Ann Surg. 2022 Jul 15.

doi: 10.1097/SLA.0000000000005466. Online ahead of print

<2021>

[43] Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

Yoon S, Kim M, Hong YS, Kim HS, Kim ST, Kim J, Yun H, Yoo C, Ahn HK, Kim HS, Lee IH, Kim IH, Park I, Jeong JH, Cheon J, Kim JW, Yun J, Lim SM, Cha Y, Jang SJ, Zang DY, Kim TW, Kang JH, Kim JH. Cancer Res Treat.  2021 Dec 13. doi: 10.4143/crt.2021.1115

[42] Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer

Lee J, Koom WS, Byun HK, Yang G, Kim MS, Park EJ, Ahn JB, Beom SH, Kim HS, Shin SJ, Kim K, Chang JS. Clin Colorectal Cancer. 2021 Nov 18th.

[41] Efficacy and Safety of Atezolizumab plus Bevacizumab in Korean Patients with Advanced Hepatocellular Carcinoma

Cheon J, Yoo C, Hong JY, Kim HS, Lee D, Lee MA, Kim JW, Kim I, Oh Sh, H Jun, Chon HJ, Lim HY. Liver Int. 2022;42(3):674-681 doi: 10.1111/liv.15102.

[40] Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer

Lee JB*, Kim K*, Cho HY, Kim D, Kim WK, Yong D, Lee H, Yoon SS, Han DH, Han YD, Paik S, Jang Mi#, Kim HS#, Ahn JB#. Sci Rep.  2021 Oct 12;11(1):20263. doi: 10.1038/s41598-021-98941-6. (*co-first, #co-correspondence)

[39] Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations.

Kim KH*, Kim HS*, Kim SS, Shim HS, Yang AJ, Lee JJB, Yoon HI, Ahn JB#, Chang JS#. Cancer Res Treat. 2021 Jun.

https://doi.org/10.4143/crt.2020.1247 (*co-first)

[38] Upfront chemotherapy and short-course radiotherapy with delayed surgery for locally advanced rectal cancer with synchronous liver metastases

Bae HW, Kim HS, Yang SY, Kim HS, Shin SJ, Chang JS, Koom WS, Kim NK. Eur J Surg Oncol. 2021 May. https://doi.org/10.1016/j.ejs

[37] Role of Preoperative Chemoradiotherapy in Clinical Stage II/III Rectal Cancer Patients Undergoing Total Mesorectal Excision: A Retrospective Propensity Score Analysis.
Lee JB*, Kim HS*, Ham A, Chang JS, Shin SJ, Beom S, Koom WS, Kim T, Han YD, Han DH, Hur H, Min BS, Lee KY, Kim NK, Park YR, Lim JS#, Ahn JB#. Front. Oncol.  2021 Jan. https://doi.org/10.3389/fonc.2020.609313 (*co-first)

​

<2020>

[36] Extracellular vesicle and particle isolation from human and murine cell lines, tissues, and bodily fluids.

Bojmar L*, Kim HS*, Tobias GC, Vatter FAP, Lucotti S, Gyan KE, Kenific CM, Wan Z, Kim K, Kim D, Hernandez J, Pascual V, Heaton T, Quaglia MP, Kelsen D, Trippett TM, Jones D, Jarnagin WR, Matei IR, Zhang H#, Hoshino A#, Lyden D#. STAR Protocols. 2020 Dec 25. doi: 10.1016/j.xpro.2020.100225.

(*co-first) Dr. Kyung-A Kim and DooA Kim worked so hard to generate Figure 3.

[35] Clinical features and KRAS mutation in colorectal cancer with bone metastasis.

Park H, Chun YK, Kim HS, Kim JH, Lee CK, Beom SH, Shin SJ, Ahn JB. Sci Rep. 2020 Dec 3;10(1):21180.

[34] Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells.

Kim KH*, Kim HS*, Kim SC*, Kim D, Kim YB, Chung HC, Rha SY. Front. Oncol. 2020 Sep 11;10:562284. doi: 10.3389/fonc.2020.562284. (*co-first)

[33] Pre-screening of patient-reported symptoms using the Edmonton Symptom Assessment System in outpatient palliative cancer care.

Lee G*, Kim HS*, Lee SW*, Park YR, Kim EH, Lee B, Hu YJ, Kim KA, Kim D, Cho HY, Kang B, Choi HJ. Eur J Cancer Care. 2020 Nov;29(6):e13305. doi: 10.1111/ecc.13305. (*co-first)

[32] Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.

Kim HR, Kang HN, Yun MR, Ju KY, Choi JW, Jung DM, Pyo KH, Hong MH, Ahn MJ, Sun JM, Kim HS, Kim J, Yoo J, Kim KR, Koh YW, Kim SH, Choi EC, Yoon SO, Shim HS, Paik S, Kim TM, Cho BC. Br J Cancer. 2020 Dec;123(12):1720-1729.

[31] Prognosis of Synchronous Colorectal Liver Metastases After Simultaneous Curative-Intent Surgery According to Primary Tumor Location and KRAS Mutational Status.

Kim HS, Lee JM, Kim HS, Yang SY, Han YD, Cho MS, Hur H, Min BS, Lee KY, Kim NK. Ann Surg Oncol. 2020 Dec;27(13):5150-5158.

[30] Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.

Hoshino A*#, Kim HS*, Bojmar L*, Gyan KE*, ..., Bromberg J, Costa-Silva B, Peinado H, Kang Y, Garcia BA, O'Reilly EM, Kelsen D, Trippett TM, Jones DR, Matei IR, Jarnagin WR#, Lyden D#. Cell. 2020 Aug 20;182(4):1044-1061. (*co-first)

[29] A phase II study of avelumab monotherapy in patients with mismatch repair-deficient/microsatellite instability-high or POLE-mutated metastatic or    unresectable colorectal cancer.
Kim JH, Kim SY, Baek JY, Cha YJ, Ahn JB, Kim HS, Lee KW, Kim JW, Kim TY, Chang WJ, Park JO, Kim J, Kim JE, Hong YS, Kim YH, Kim TW.

Cancer Res Treat. 2020 Oct;52(4):1135-1144.

[28] Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB*, Kim HS*, Jung I, Shin SJ, Beom SH, Chang JS, Koom WS, Kim TI, Hur H, Min BS, Kim NK, Park S, Jeong SY, Baek JH, Kim SH, Lim JS, Lee KY#, Ahn JB#. Trials. 2020 Apr;21(1):320 (*co-first)

​

<2019>

[27] Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis.
Rodrigues G, Hoshino A, Kenific CM, Matei IR, Steiner L, Freitas D, Kim HS, Oxley PR, Scandariato I, Casanova-Salas I, Dai J, Badwe CR, Gril B,  Tešić Mark M, Dill BD, Molina H, Zhang H, Benito-Martin A, Bojmar L, Ararso Y, Offer K, LaPlant Q, Buehring W, Wang H, Jiang X, Lu TM, Liu Y, Sabari JK, Shin SJ, Narula N, Ginter PS, Rajasekhar VK, Healey JH, Meylan E, Costa-Silva B, Wang SE, Rafii S, Altorki NK, Rudin CM, Jones DR, Steeg PS, Peinado H, Ghajar CM, Bromberg J, de Sousa M, Pisapia D, Lyden D. Nat Cell Biol.  2019 Nov;21(11):1403-1412

[26] Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation.
Kim CG, Lee HW, Choi HJ, Lee JI, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim HS, Kim KH, Choi SJ, Kim Y, Lee KS, Kim GM, Kim MD, Won JY, Lee DY, Kim BK. Cancer Med. 2019 Sep;8(11):5023-5032

​

<2018>

[25] Complex polymorphisms in endocytosis genes suggest alpha-cyclodextrin as a treatment for breast cancer.

Wittkowski KM, Dadurian C, Seybold MP, Kim HS, Hoshino A, Lyden D. PLoS One. 2018 Jul;13(7):e0199012

[24] MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver  metastasis.

Kim HS, Chon HJ, Kim H, Shin SJ, Wacheck V, Gruver AM, Kim JS, Rha SY, Chung HC. J Surg Oncol. 2018 Jun;117(8):1679-1686. (first)

[23] Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information. 
Kim S*, Kim HS*, Kim E, Lee MG, Shin E, Paik S, Kim S. Ann Oncol. 2018 Apr 1;29(4):1030-1036. (*co-first)

[22] Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth.  
Kim W, Lee S, Kim HS, Song M, Cha YH, Kim YH, Shin J, Lee ES, Joo Y, Song JJ, Choi EJ, Choi JW, Lee J, Kang M, Yook JI, Lee MG, Kim  YS, Paik S, Kim HH. Genome Res. 2018 Jan 11. [E-pub]

[21] Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation.
Zhang H, Freitas D*, Kim HS*, Fabijanic K, Li Z, Chen H, Mark MT, Molina H, Martin AB, Bojmar L, Fang J, Rampersaud S, Hoshino A, Matei I, Kenific CM, Nakajima M, Mutvei AP, Sansone P, Buehring W, Wang H, Jimenez JP, Cohen-Gould L, Paknejad N, Brendel M, Manova-Todorova K, Magalhães A, Ferreira JA, Osório H, Silva AM, Massey A, Cubillos-Ruiz JR, Galletti G, Giannakakou P, Cuervo AM, Blenis J, Schwartz R, Brady MS, Peinado H, Bromberg J, Matsui H, Reis CA, Lyden D. Nat Cell Biol. 2018 Mar;20(3):332-343. (*co-second)

​

<2017>

[20] A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD. 
Kim HS*, Cheon JH*, Jung ES*, Park J, Aum S, Park SJ, Eun S, Lee J, Rüther U, Yeo GSH, Ma M, Park KS, Naito T, Kakuta Y, Lee JH, Kim WH, Lee MG. Gut. 2017 Nov;66(11):1926-1935. (*co-first)

[19] Unshielding exosomal RNA unleashes tumor growth and metastasis.
Matei I*, Kim HS*, Lyden D. Cell. 2017 Jul 13;170(2):223-225. (*co-first)

[18] Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. 
Kim HS*, Jung M*, Kang HN*, Kim H, Park CW, Kim SM, Shin SJ, Kim SH, Kim SG, Kim EK, Yun MR, Zheng Z, Chung KY, Greenbowe J, Ali SM, Kim TM, Cho BC#. Oncogene. 2017 Jun 8;36(23):3334-3345 (*co-first)

​

<2016>

[17] Extracellular vesicles in cancer: Cell-to-cell mediators of metastasis.
Becker A*, Thakur BK*, Weiss JM, Kim HS, Peinado H, Lyden D. Cancer Cell. 2016 Dec 12;30(6):836-848.

[16] Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. 
Huang KK, Jang KW, Kim S, Kim HS, Kim SM, Kwon HJ, Kim HR, Yun HJ, Ahn MJ, Park KU, Ramnarayanan K, McPherson JR, Zhang S, Rhee JK, Vettore AL, Das K, Ishimoto T, Kim JH, Koh YW, Kim SH, Choi EC, Teh BT, Rozen SG, Kim TM, Tan P, Cho BC. Sci Rep. 2016 Jan 21;6:19552.

​

<2015>

[15] Novel COCH p.V123E mutation, causative of DFNA9 sensorineural hearing loss and vestibular disorder, shows impaired cochlin post-translational cleavage and secretion.
Jung J*, Kim HS*, Lee MG, Yang EJ, Choi JY. Hum Mutat. 2015 Dec;36(12):1168-75. (*co-first)

[14] microDuMIP: target-enrichment technique for microarray-based duplex molecular inversion probes.
Yoon JK*, Ahn J*, Kim HS*, Han SM, Jang H, Lee MG, Lee JH, Bang D. Nucleic Acids Res. 2015 Mar 11;43(5):e28. (*co-first)

[13] Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and
neck.
Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC. Clin Cancer Res. 2015 Feb 1;21(3):544-52. (first)
(“Highlights” Selected Articles from CCR Vol. 21 Num. 3)

​

<2014>

[12] Ifosfamide-induced Fanconi syndrome with diabetes insipidus.
Leem AY, Kim HS, Yoo BW, Kang BD, Kim MH, Rha SY, Kim HS. Korean J Intern Med. 2014 Mar;29(2):246-9.

[11] Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers. 
Ahn JW*, Kim HS*, Yoon JK*, Jang H, Han SM, Eun S, Shim HS, Kim HJ, Kim DJ, Lee JG, Lee CY, Bae MK, Chung KY, Jung JY, Kim EY, Kim SK, Chang J, Kim HR, Kim JH, Lee MG, Cho BC, Lee JH, Bang D. Genome Med. 2014 Feb 27;6(2):18. (*co-first)

​

<2013>

[10] Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.
 Kim HS, Shin SJ, Kim JH, Kim H, Choi HJ. Tohoku J Exp Med. 2013 Sep;231(1):21-8. (first)

[9] Changing treatment patterns in elderly patients with resectable colon cancer.
 Kim GM, Ahn JB, Rha SY, Kim HS, Kang B, Kim MW, Choi SY, Roh JK, Chung HC, Kim NK, Shin SJ. Asia Pac J Clin Oncol. 2013 Sep;9(3):265-72

[8] Factors associated with diabetic retinopathy and nephropathy screening in Korea: the Third and Fourth Korea National Health and Nutrition Examination Survey (KNHANES III and IV).
Rim TH, Byun IH, Kim HS, Lee SY, Yoon JS. J Korean Med Sci. 2013 Jun;28(6):814-20.

[7] Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. 
 Lim S, Cho BC, Jung JY, Kim GM, Kim SH, Kim HR, Kim HS, Lim SM, Park JS, Lee JH, Kim D, Kim EY, Park MS, Kim YS, Kim SK, Chang J, Kim JH.
Lung Cancer. 2013 Jun;80(3):313-8.

[6] Personalized therapy on the horizon for squamous cell carcinoma of the lung.
Kim HS, Mitsudomi T, Soo RA, Cho BC. Lung Cancer. 2013 Jun;80(3):249-55. (first)

[5] Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. 
Kim HS, Shin SJ, Kim SC, An S, Rha SY, Ahn JB, Cho BC, Choi HJ, Sohn JH, Kim HS, Chung HC, Kim JH, Roh JK, Lee S. Support Care Cancer. 2013 Jun;21(6):1751-9 (first)

[4] Flecainide-associated bradycardia-dependent torsade de pointes: another potential mechanism of proarrhythmia. 
Kim HS, Pak HN, Park JS, Kim SS. Pacing Clin Electrophysiol. 2013 Mar;36(3):e84-6. (first)

​

<2012>

[3] The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
Kim HS, Kim HR, Kim GM, Kim HS, Koh YW, Kim SH, Choi EC, Hong YK, Sung JH, Kim SM, Kim JH, Cho BC. Cancer Chemother Pharmacol. 2012
Oct;70(4):539-46. (first)

[2] Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. 
Kim HS*, Kim SC*, Kim SJ, Park CH, Jeung HC, Kim YB, Ahn JB, Chung HC, Rha SY. BMC Genomics. 2012 Jul 30;13:348. (*co-first)

​

<2011>

[1] Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis.      
 Kim HS, Kang SH, Park CH, Yang WI, Jeung HC, Chung HC, Roh JK, Ahn JB, Kim NK, Min BS, Rha SY. Oncol Rep. 2011 Mar;25(3):717-27. (first)